Leerink Swann initiated coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report released on Monday morning, MarketBeat.com reports. The brokerage issued an underperform rating and a $28.00 price objective on the stock. Leerink Swann also issued estimates for Deciphera Pharmaceuticals’ Q3 2018 earnings at ($0.64) EPS, Q4 2018 earnings at ($0.75) EPS, FY2018 earnings at ($2.70) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.08) EPS and FY2022 earnings at ($2.39) EPS.
A number of other research analysts also recently commented on the stock. Piper Jaffray Companies increased their price target on shares of Deciphera Pharmaceuticals to $50.00 and gave the company an overweight rating in a report on Tuesday, June 12th. Guggenheim began coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 17th. They issued a buy rating for the company. BidaskClub downgraded shares of Deciphera Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, August 22nd. Cantor Fitzgerald began coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, September 6th. They issued a buy rating and a $53.00 price target for the company. Finally, Canaccord Genuity began coverage on shares of Deciphera Pharmaceuticals in a report on Tuesday, August 7th. They issued a buy rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. Deciphera Pharmaceuticals currently has a consensus rating of Buy and an average price target of $48.09.
DCPH opened at $38.49 on Monday. Deciphera Pharmaceuticals has a 52 week low of $15.15 and a 52 week high of $45.61. The stock has a market cap of $1.44 billion and a price-to-earnings ratio of -12.94. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05.
Large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its holdings in shares of Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after acquiring an additional 1,982 shares during the last quarter. SG Americas Securities LLC bought a new stake in Deciphera Pharmaceuticals in the first quarter worth about $152,000. New York State Common Retirement Fund lifted its stake in Deciphera Pharmaceuticals by 37.5% in the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after purchasing an additional 2,700 shares during the last quarter. Trexquant Investment LP bought a new stake in Deciphera Pharmaceuticals in the second quarter worth about $203,000. Finally, Rhumbline Advisers bought a new stake in Deciphera Pharmaceuticals in the second quarter worth about $301,000. 53.53% of the stock is owned by hedge funds and other institutional investors.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Read More: What Does Beta Mean In Stock Selection
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.